NCT06931340 2026-03-04
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
Clinical Trials
7 trialsNCT04423211 2026-03-02
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04134260 2026-01-14
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NRG Oncology
Phase 3 Recruiting
NCT06592924 2026-01-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06274047 2025-10-30
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT03903835 2025-04-09
ProBio
Karolinska Institutet
Phase 3 Recruiting
NCT06496581 2024-12-20
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
UNICANCER
Phase 3 Recruiting